Business
Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device
Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n\n LOS ANGELES, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of critical limb ischemia (CLI) in mice.\n Animals treated three times per day with the Company's Pulsed Electromagnetic Fields (PEMF) device had significantly higher blood flow (ratio of blood flow of the ischemic limb to blood flow of non-ischemic limb) at day 7 and 14 (57% and 71%, versus 36% and 52%) versus the controls. Furthermore, animals treated with PEMF three times per day had significantly improved foot movement scores and less tissue damage in the ischemic hind limb versus the controls. Critical Limb Ischemia (CLI) is an advanced stage of Peripheral Artery Disease (PAD), a common vascular disease that affects approximately 200 million people worldwide, where fatty deposits block arteries in the legs, leading to pain, non-healing ulcers, and gangrene. Worldwide, approximately 22-30 million people suffer from CLI, according to The Sage Group. Patients with CLI have a high risk of amputation and death, and patients unsuitable for revascularization are left with no adequate treatment options. Endonovo Therapeutics is currently developing a pipeline of non-invasive medical devices, Electroceuticals™, for the treatment of vascular diseases, including cardiovascular and cerebrovascular disease. The Company's Pulsed Electromagnetic Fields (PEMF) technology has been evaluated in a pilot clinical trial in 30 patients with ischemic cardiomyopathy and failed medical therapy and revascularization options (\"no option patients\"). Patients in the active cohort demonstrated significant improvements in function, including improved Seattle Angina Questionnaire (SAQ) subscales for Anginal Frequency and severity, and Physical Activity. Furthermore, 3 patients in the active cohort had a 12-25% increase in perfusion compared to the sham group. \"We believe our non-invasive medical devices will address significantly unmet medical needs in vascular diseases, including peripheral artery, cardiovascular and cerebrovascular disease,\" said Endonovo CEO, Alan Collier. \"Currently up to 40% of patients with critical limb ischemia are not eligible for revascularization and h...